The BD Alaris infusion set FDA alert turns on a practical question for hospitals: which kits on the ward contain the affected sets, and how should low-rate infusions be managed until they are replaced? The FDA published two early alerts on 20 October 2026 about Cardinal Health Presource kits that contain BD Alaris pump infusion sets covered by a BD and CareFusion 303 recall, and it lists actions that biomedical, pharmacy and nursing teams may want to review.
Key takeaways: the BD Alaris infusion set FDA alert for hospital teams
- The alerts concern Presource kits containing affected BD Alaris pump infusion sets; the kit list is in a linked FDA attachment.
- The FDA says deviations are most common at rates under 1 mL per hour and at boluses of 5 mL or less.
- Higher-risk patients include neonates, paediatric patients and critically ill patients.
- The FDA lists mitigation steps drawn from the BD Alaris user manual, versions 12.3 to 12.6.
- BD reported no serious injuries or deaths as of 19 August 2026.
Step one: finding the affected kits under the BD Alaris infusion set FDA alert
The FDA’s first recommended action is to identify affected product in inventory. Because the sets are inside convenience kits, this may mean checking kit contents and not only loose infusion sets. The agency links to a full list of affected devices; the text of the alerts does not name the kits. Cardinal Health’s correction guidance asks customers to locate and quarantine affected kits and alert clinicians. The FDA pages are here: use instructions alert and kit correction alert.
Step two: managing clinical use under the BD Alaris infusion set FDA alert
The FDA says users should review BD’s pump infusion set performance disclosures and adjust clinical use, set selection or pump use as needed. If Alaris performance is not clinically appropriate, it suggests an alternative pump such as the BD Alaris Syringe Module or another syringe pump. If no syringe pump is available, the sets may be used with caution, enhanced clinical monitoring and adherence to BD’s earlier warnings. Those are the agency’s statements, not our recommendations.
Mitigation steps listed in the BD Alaris infusion set FDA alert
The FDA reproduces risk mitigation steps from the BD Alaris Infusion System User Manual. In summary, as the agency states them:
- Rate and bolus accuracy: do not hang the solution container below the pump module or more than 21 inches above its top.
- Time to alarm: place tubing directly over the pressure sensors, confirm all clamps are open with no kinks or collapses outside the pump, confirm drops are flowing in the drip chamber, and open the vent if applicable.
- Pressure setting: do not use Selectable pressure mode above 50 mmHg for rates under 10 mL per hour.
- Post-occlusion bolus: when clearing an occlusion, turn fluid flow to the patient off and relieve pressure by disconnecting tubing through a stopcock if present, weighing the risk of disconnection against the risk of an unintended bolus.
Clinical teams should read the full FDA text and BD’s documents before relying on this summary.
Step three: labelling and communication for the BD Alaris infusion set FDA alert
The correction alert says Cardinal Health recommends affixing a visible warning label on the front of each Presource kit instructing clinicians to remove and discard the recalled components, and that distributors who passed on affected kits should notify their customers. Hospitals will want to make sure that clinicians, pharmacists and procurement staff all receive the same message.
What the BD Alaris infusion set FDA alert means for low-flow settings
The risk is concentrated where flow is small and doses are potent. The FDA names antiarrhythmics and blood-pressure support medicines as examples of infusions given to high-risk patients at low rates or volumes. In those settings, under-delivery or delayed alarms can matter quickly. We do not know how many such infusions use affected sets, and the alerts do not say.
General background: infusion pumps and infusion sets
An infusion pump controls the rate of a fluid or medicine given through a tube. The tube and its components, called the infusion set, affect how the pump measures and delivers the fluid. A change in the performance of the set can therefore change delivery even when the pump is working. This is general background and not a finding in the alert. Related coverage is in our medical device section.
Our analysis: operational checks matter more than headlines
In our assessment, the BD Alaris infusion set FDA alert is mainly an inventory and workflow problem. The most useful actions are finding kits, labelling or replacing them, and making sure low-rate infusions have a documented plan. The alert does not support a general loss of confidence in all infusion pumps, and it does not say the pumps themselves have failed.
We have not seen BD’s customer letters, and we do not know how long replacement sets will take. Hospitals should follow the manufacturer and FDA instructions over any summary, including ours.
What is not disclosed about the BD Alaris infusion set FDA alert
- Kit names and catalogue numbers in the alert text.
- How many kits have been distributed.
- Any injuries or deaths after 19 August 2026.
- The cause of the overestimated performance.
- The expected date for replacement sets.
Risks and caveats of the BD Alaris infusion set FDA alert
The FDA says it is still reviewing the issue and may update its pages. Our summary may omit details found in the FDA text and in BD’s letters. This is news reporting and not clinical advice.
What to watch next after the BD Alaris infusion set FDA alert
- Updates to the FDA alerts.
- Replacement or relabelling timelines from Cardinal Health and BD.
- Reports to MedWatch.
- Hospital guidance for neonatal and intensive-care units.
FAQ
What should hospitals check first after the BD Alaris infusion set FDA alert?
The FDA says to identify affected product in inventory, using its list of affected devices.
Which patients are most at risk?
Neonates, paediatric patients and critically ill patients, according to the FDA.
Where can problems be reported?
To the FDA’s MedWatch program, or to Cardinal Health for US customers.
How we reported this: we relied on the two FDA early alerts and attributed every instruction and risk statement to them. Last updated 23 October 2026. This is news reporting and not advice.
